An epidemiological study on the course of disease and therapeutic considerations in relapsing–remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)

BACKGROUND: In relapsing–remitting multiple sclerosis (RRMS), ‘no evidence of disease activity’ (NEDA) is regarded as a key treatment goal. The increasing number of treatments allows for individualized treatment optimization in patients with suboptimal response to first-line disease-modifying therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Stephan, Koehler, Jürgen, Winterstein, Christine, Schicklmaier, Petra, Kallmann, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788096/
https://www.ncbi.nlm.nih.gov/pubmed/29399053
http://dx.doi.org/10.1177/1756285617749802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788096/
https://www.ncbi.nlm.nih.gov/pubmed/29399053
http://dx.doi.org/10.1177/1756285617749802

Ejemplares similares